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Breast cancer (BC) is one of the leading cancers
among women. 90% of BC related deaths are due to
metastasis, irrespective of whether metastasis was
diagnosed at the beginning or if it developed later. BC
stem cells are a subset of cancer cells responsible for
tumor initiation, progression and metastasis. They are
resistant to conventional chemo- and radiotherapies,
and so therapeutic strategies targeting BC stem cells
hold great clinical potential. Salinomycin (SAL) is a
polyether ionophore antibiotic known for its wide
spectrum of biological properties, including anti-BC
stem cell activity. In order to further improve the activity
of SAL and increase its selectivity, a library of 17 novel
SAL analogues has been synthesized. From those we
identified eight that were more potent towards the
MDA-MB-231 BC cell line than parent molecule. Of
those double-modified analogues, compound 17 was
found to be more effective than SAL against the
majority of cancer cell lines included in the NCI-60
Human Tumor Cell Line Panel. Additionally, compound
17 was more potent than SAL in inhibiting BC cell
renewal, migration and in inducing selective loss of the
CD44+/CD24- stem cell population in both cell
monolayer and 3D organoid cultures. Further studies
revealed that analog 17 induced features of apoptotic
cell death and increased the autophagy marker LC3.
Our findings highlight the therapeutic potential of SAL
analogues towards BC stem cells.
 Analog 17 was more potent than SAL towards the
NCI breast cancer sub-panel
 Analog 17 showed improved anti-colony formation,
and anti-migratory properties over the parent SAL
 Analog 17 was superior over SAL in reducing
CD44high/CD24low stem-like population in 2D and 3D
culture
 Salinomycin and analog 17 induced characteristics
of apoptotic cell death in 2D and 3D culture
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Figure 4. MDA-MB-231 cells or organoids were treated with 25 µM 1, 14 µM 2, or 5 µM 17 for the times indicated, and extracts were
prepared and subjected to immunoblotting for PARP or Bcl-2. GAPDH served as a loading control.
Figure 5. Flow cytometry analysis on the expression of
CD44high/CD24lowstem-like populations. (A) Cells were triple
stained with anti-CD44-PE, anti-CD24-FITC and propidium iodide.
Representative cytograms are shown. (B) The ratio of
CD44high/CD24low MDA-MB-231 cells after treatment with 0.1%
DMSO (vehicle), 2.5 μM 1, 1.4 μM 2 or 0.5 μM 17 for 48 h. Data
represents means ± SD (n = 3),**p ≤ 0.01, *** p ≤ 0.001. (C)
Scheme of organoids acquisition and culturing. Pictures were
taken at 2x magnification. Scale bar, 2000 μm. (D) Single-cells
dispersed organoids were stained as described above.
Representative cytograms are shown. (E) The ratio of
CD44high/CD24low cut organoid cells after treatment with 0.1%
DMSO (vehicle), 2.5 μM 1, or 0.5 μM 17 for 48 h. Data represents
means ± SD (n =3), *p≤ 0.05, ***p ≤ 0.001.
Synthesis of single- and double modified
salinomycin analogs
Salinomycin and its analogs reduce colony
forming ability of breast cancer cells
Salinomycin and its analogs induce DNA
fragmentation
Figure 1. MDA-MB-231 cells were treated with DMSO, 1 and its
selected analogues for 24, 48 or 72 h and subjected to propidium
iodide (PI) staining and flow cytometry. Percent of cells observed
in different phases of cell cycle determined by PI staining is
shown. Data represent mean ± SD (n = 3) *p ≤ 0.05, **p ≤ 0.01,
*** p ≤ 0.001, **** p ≤ 0.0001.
Salinomycin and its analogs reduce the
stemness potential of breast cancer cells
Figure 2. Wound healing assay was employed to evaluate
migration properties of MDA-MB-231 cells after treatment with
0.1% DMSO salinomycin (1) and 0.1% DMSO (vehicle), 2.5 µM
1, 1.4 µM 2 or 0.5 µM 17 for 48 h. Wound has been created on a
confluent cell monolayer and images were acquired at zero, four,
24, and 48 hour time points. The experiment was performed in
duplicate. Data represents means ± SD (n = 2), *p ≤ 0.05.
Figure 3. Effect of salinomycin (1) and analogs 2 and 17 on
clonogenic potential of MDA-MB-231 cells. MDA-MB-231 cells
were treated with 0.1% DMSO, 1 (2.5 µM), 2 (1.4 µM) or 17 (0.5
µM) for 6 h, 24 h, 48 h and 72 h. At the end of the incubation, cells
were harvested and re-seeded in 6-well plates at 250 cells/well.
After 13 days, cells were fixed and stained with 0.5% crystal violet
methanol solution. Colonies, defined by group of more than 50
cells, were counted manually for each well and normalized to the
control. Data represent mean values ± SD (n = 6). *p ≤ 0.05, **p ≤
0.01, *** p ≤ 0.001, **** p ≤ 0.0001.
Salinomycin analogs are more potent than
the parent compound
Salinomycin and its analogs decrease
breast cancer cell migratory properties
Table 1. Antiproliferative activity (IC50) and selectivity index (SI)
values of salinomycin (1), and its analogues.
IC50 value is defined as the concentration of the compound which
induces 50% growth inhibition. SI values were calculated for each
compound employing following formula: SI = IC50 for normal cell
line MCF 10A / IC50 for cancerous cell line. A favorable IC50 > 1.00
indicates a compound with efficacy towards tumor cells greater
than towards normal cell line.
Analog 17 show higher activity than
salinomycin towards NCI breast cancer panel
Table 2. Anti-growth potency (GI50 in µM) for compounds 13 and
17 in the five dose human cancer cell panel assay.
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Salinomycin and analog 17 induce apoptotic
cell death
*Due to their promising activity compounds 1 and 17 were
selected for the repeat of 5-dose assay and n=2 ± SD is shown.
